Curocell (XKRX:372320) Additional Paid-In Capital : ₩215,015.96 Mil(As of Mar. 2025)

View and export this data going back to 2023. Start your Free Trial

What is Curocell Additional Paid-In Capital?

Curocell's quarterly additional paid-in capital increased from Sep. 2024 (₩213,358.62 Mil) to Dec. 2024 (₩215,016.37 Mil) but then stayed the same from Dec. 2024 (₩215,016.37 Mil) to Mar. 2025 (₩215,015.96 Mil).

Curocell's annual additional paid-in capital increased from Dec. 2022 (₩70,468.75 Mil) to Dec. 2023 (₩205,659.66 Mil) and increased from Dec. 2023 (₩205,659.66 Mil) to Dec. 2024 (₩215,016.37 Mil).

Curocell Additional Paid-In Capital Historical Data

The historical data trend for Curocell's Additional Paid-In Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Curocell Additional Paid-In Capital Chart

Curocell Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Additional Paid-In Capital

Get a 7-Day Free Trial

38,713.03

70,427.23

70,468.75

205,659.66

215,016.37

Curocell Quarterly Data
	Dec19	Dec20	Dec21	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
Additional Paid-In Capital	Get a 7-Day Free Trial								205,659.66	212,913.10	213,358.62	215,016.37	215,015.96

Curocell Additional Paid-In Capital Calculation

Capital that a company raises in a financing round in excess of the capital's par value. The account represents the excess paid by an investor over the par-value price of a stock issue. Additional paid-in-capital can arise from issuing either preferred or common stock.

Additional Paid-In Capital is calculated as

Additional Paid-In Capital

(Issue Price

Par Value)

Shares Outstanding (Diluted Average)

Curocell Additional Paid-In Capital Related Terms

Thank you for viewing the detailed overview of Curocell's Additional Paid-In Capital provided by GuruFocus.com. Please click on the following links to see related term pages.

Curocell Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Curocell Inc (XKRX:372320) » Definitions » Additional Paid-In Capital

Comparable Companies

Traded in Other Exchanges

N/A

Address

11, Gukjegwahak 16-ro, Yuseong-gu, Daejeon, KOR, 34002

Website

https://www.curocellbtx.com

Curocell Inc is engaged in medical and pharmaceutical research and development. The company is into development of CAR-T treatments that enhance the natural function of immune cells to eliminate cancer cells through genetic manipulation of human immune cells.

Curocell Headlines

No Headlines